Introduction
Lower respiratory tract infection (LRTI) is a common cause of mortality worldwide. Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are typical aetiological agents in respiratory tract infection (RTI), and strains resistant to antimicrobial agents are increasingly being isolated from infected patients. [1] [2] [3] [4] [5] Resistance may compromise the efficacy of the drugs, typically thelactams and macrolides, traditionally used as the treatment of choice in RTI. As such, there is currently a need for new drugs that provide antimicrobial cover which includes these more resistant respiratory pathogens.
Newer-generation quinolones have recently become available, which are potent against a wider range of Grampositive organisms than older members of this class.
However, their clinical efficacy in RTI is threatened by the increase in the reported incidence of pneumococcal resistance to several of these agents. 6, 7 Gemifloxacin is a potent, novel quinolone with broad-spectrum antibacterial activity against both Gram-negative and Gram-positive pathogens, 8 including strains resistant to other classes of antimicrobial agents. [9] [10] [11] [12] Of particular interest is the greater potency of gemifloxacin against several common respiratory pathogens, which indicates that it may have potential value in the treatment of RTI. [11] [12] [13] [14] Penicillin-resistant pneumococci and amoxycillin-resistant H. influenzae are becoming increasingly prevalent in cases of LRTI 15, 16 and pose a considerable therapeutic challenge to clinicians. As antimicrobial activity alone is not a predictor of therapeutic efficacy, animal models of infection are important for assessing the potential efficacy
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Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection The in vivo efficacy of the novel quinolone gemifloxacin (SB-265805) was examined in a rat respiratory tract infection (RTI) model against four strains of Streptococcus pneumoniae and two strains of Haemophilus influenzae with varying susceptibilities to standard antimicrobial agents. Animals were infected intrabronchially to produce pneumonia and therapy with oral gemifloxacin, amoxycillin-clavulanate, ciprofloxacin, cefuroxime, azithromycin, trovafloxacin, grepafloxacin or levofloxacin was started 24 h after infection. The doses administered were chosen to approximate in the rat the serum or tissue concentrations measured in humans following therapeutic dosing. Therapy continued once-or twice-daily for 3 days, and approximately 17 h after the end of therapy the lungs were excised for bacterial enumeration. Following infection with strains of S. pneumoniae, gemifloxacin produced a 3-5 log reduction in bacterial numbers compared with untreated animals. Gemifloxacin was as effective as amoxycillinclavulanate, and was as potent or more potent than all other comparators. Notably, the quinolone agents trovafloxacin, ciprofloxacin, grepafloxacin and levofloxacin were significantly less effective (P < 0.01) than gemifloxacin: these agents reduced bacterial numbers by 3 log compared with untreated animals. Gemifloxacin produced a marked response against H. influenzae infection, reducing bacterial numbers significantly (P < 0.01) compared with untreated controls. Gemifloxacin was significantly more potent than cefuroxime and azithromycin. None of the other comparator agents was more potent than gemifloxacin. The excellent efficacy seen in these experimental models of RTI with S. pneumoniae and H. influenzae confirms the in vitro activity of gemifloxacin against these organisms. This indicates that gemifloxacin may be of significant benefit in the treatment of RTI.
of new agents against such pathogens. This paper will consider the efficacy of gemifloxacin compared with that of cefuroxime, amoxycillin-clavulanate, azithromycin, ciprofloxacin, grepafloxacin, levofloxacin and trovafloxacin in rat models of RTI caused by strains of S. pneumoniae or H. influenzae with varying antimicrobial susceptibility profiles.
Materials and methods

Bacterial strains
The infecting strains used in this study were S. pneumoniae 1629 (penicillin-susceptible), 10127 (penicillin-susceptible), 406081 (penicillin-and macrolide-resistant) and 404053 (penicillin-and macrolide-resistant), and H. influenzae Chesterfield ( -lactamase-negative, ampicillin-resistant) and LA 85021 ( -lactamase-positive). The strains used were either laboratory strains or recent clinical isolates obtained from the Alexander Project 17 and were chosen for their proven ability to produce infection in animal models and for their antimicrobial susceptibility profiles (Table I ). All test strains were susceptible to ciprofloxacin. Susceptibility tests were performed by broth microdilution in accordance with NCCLS recommended procedures.
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Antimicrobial agents
Gemifloxacin (SB 265805-S) was supplied by SmithKline Beecham Pharmaceuticals, Harlow, UK. Amoxycillin trihydrate and potassium clavulanate were supplied by SmithKline Beecham Pharmaceuticals, Worthing, UK. Ciprofloxacin (Cipro; Bayer, West Haven, CT, USA), grepafloxacin (Vaxar; Glaxo Wellcome, Research Triangle Park, NC, USA), levofloxacin (Levaquin; Ortho McNeil Pharmaceuticals, Raritan, NJ, USA), trovafloxacin (Trovan; Pfizer, New York, NY, USA), azithromycin (Zithromax; Pfizer) and cefuroxime (Ceftin; Glaxo Wellcome) were used as commercial preparations. The compounds were prepared in phosphate-buffered saline (PBS). Gemifloxacin was administered as the mesylate salt and all other antimicrobial agents were used as pure free-acid equivalents.
Animals
Specific pathogen-free male Sprague-Dawley CD rats weighing approximately 100 g were supplied by Charles River, Raleigh, NC, USA. There were six animals in each treatment group. All procedures were performed in accordance with protocols approved by the SmithKline Beecham Institutional Animal Care and Use Committee, and met or exceeded the standards of the American Association for the Accreditation of Laboratory Animal Care, the United States Department of Health and Human Services, and all local and federal animal welfare laws. 
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Induction of infection
Experimental respiratory infection was induced by standard techniques, except that animals were not rendered neutropenic. 17 Bacterial inocula were prepared by harvesting growth of S. pneumoniae from tripticase soy plates (BBL; Becton Dickinson & Co., Cockeysville, MD, USA) supplemented with 5% (v/v) sterile, defibrinated horse blood and suspending in PBS. H. influenzae was grown as an overnight culture in Mueller-Hinton broth (BBL) supplemented with 5% (v/v) Fildes extract (Becton Dickinson & Co.). Ten-fold dilutions of each organism were prepared into cooled (41°C) molten nutrient agar. Anaesthesia was induced with 3% isoflurane (Aerrane; Fort Dodge Animal Health, IO, USA) plus 1 L/min O 2 . Animals were then infected by intrabronchial instillation of 50 L of S. pneumoniae (6.0 log 10 cfu) or 100 L of H. influenzae (6.0 log 10 cfu) via intratracheal intubation.
Antimicrobial therapy
Antimicrobial doses were chosen to approximate in the rat the serum or tissue (for azithromycin) AUCs achieved in humans following therapeutic dosing, based upon total concentrations irrespective of serum binding (Table  II) . [20] [21] [22] [23] [24] [25] [26] [27] Oral therapy was initiated 24 h after infection and continued for 3 days. A further group received distilled water and served as untreated controls.
Efficacy evaluation
Approximately 17 h after the end of treatment, animals were killed and their lungs were excised and homogenized in 1 mL of PBS to permit recovery and counting of viable bacteria. Isolates obtained from the animals in which therapy failed were tested for their susceptibilities to the test antimicrobial agents using an agar dilution method. The lung homogenate samples were inoculated (20 L) in triplicate on to blood agar by a modified Miles-Misra technique. Colonies were counted following overnight incubation at 37°C, with a limit of detection of р1.7 log 10 cfu/lungs.
Data handling and analysis
For efficacy, the outcome measure for comparison of treatments was the number of bacteria in the lungs at the end of the study. All results are presented as group means with S.D. Statistical analysis was performed using Student's t test. P values of р0.05 were considered significant.
Results
S. pneumoniae infection
Following infection with S. pneumoniae 1629 (penicillinand macrolide-susceptible), bacterial numbers in untreated animals were significantly higher (6.8 Ϯ 1.2 log 10 cfu/lungs; P Ͻ 0.01) than those isolated from treatment groups ( Figure 1a ). Gemifloxacin had a potent effect, reducing the bacterial count to below the level of detection (р1.7 log 10 cfu/lungs; P Ͻ 0.01). Amoxycillin-clavulanate, cefuroxime and azithromycin were also highly effective, showing a similar level of potency to gemifloxacin (р1.7, р1.7 and 2.8 Ϯ 2.6 log 10 cfu/lungs, respectively; P Ͼ 0.05). Ciprofloxacin, grepafloxacin, levofloxacin and trovafloxacin were potent against pneumococci, but were significantly less effective than gemifloxacin (4.1 Ϯ 0.9, 3.8 Ϯ 1.7, 4.3 Ϯ 1.6 and 3.6 Ϯ 1.9 log 10 cfu/lungs, respectively; P Ͻ 0.01).
Similarly, against S. pneumoniae 10127 (penicillin-and macrolide-susceptible), gemifloxacin reduced bacterial numbers markedly compared with untreated controls (1.9 Ϯ 0.5 versus 6.4 Ϯ 1.9 log 10 cfu/lungs, respectively; P Ͻ 0.01) (Figure 1b) . Amoxycillin-clavulanate, cefuroxime and azithromycin had similar activity to gemifloxacin (р1.7, р1.7 and 2.5 log 10 cfu/lungs, respectively; P Ͼ 0.05). Of the other quinolones tested, grepafloxacin and levofloxacin produced a significant reduction in bacterial numbers compared with controls (4.1 Ϯ 1.1 and 4.1 Ϯ 1.3 log 10 cfu/lungs, respectively; P Ͻ 0.01), whereas bacterial counts in animals treated with ciprofloxacin and trovafloxacin were similar to those in untreated animals (5.6 Ϯ 1.0 and 5.3 Ϯ 1.4 log 10 cfu/lungs, respectively; P Ͼ 0.05). Gemifloxacin was significantly more potent than the other quinolones tested (P Ͻ 0.01).
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In control animals infected with S. pneumoniae 406081 (penicillin-and macrolide-resistant), bacterial counts (5.0 Ϯ 0.9 log 10 cfu/lungs) were significantly higher than those obtained in gemifloxacin-and amoxycillin-clavulanatetreated animals (P Ͻ 0.01), but similar to those observed in the remaining treatment groups (P Ͼ 0.05) (Figure 1c ). Gemifloxacin had a potent effect, reducing bacterial numbers to 2.2 Ϯ 0.6 log 10 cfu/lungs. Amoxycillin-clavulanate showed a similar effect to gemifloxacin (2.4 Ϯ 1.0 log 10 cfu/lungs; P Ͼ 0.05), whereas cefuroxime and azithromycin were significantly less effective (4.7 Ϯ 1.3 and 5.1 Ϯ 0.7 log 10 cfu/lungs, respectively; P Ͻ 0.01). The remaining quinolone agents also had poor activity, with ciprofloxacin, grepafloxacin, levofloxacin and trovafloxacin all being significantly less effective than gemifloxacin (4.1 Ϯ 1.0, 4.8 Ϯ 1.3, 4.5 Ϯ 1.8 and 5.1 Ϯ 1.0 log 10 cfu/lungs, respectively; P Ͻ 0.01).
Gemifloxacin had a potent effect against S. pneumoniae 404053 (penicillin-and macrolide-resistant), reducing bacterial counts to 1.8 Ϯ 0.2 log 10 cfu/lungs, near the level of detection; the counts were significantly lower than those in control animals (5.8 Ϯ 1.4 log 10 cfu/lungs; P Ͻ 0.01) ( Figure  1d ). This effect was significantly superior to that of all comparators (P Ͻ 0.01). Grepafloxacin, levofloxacin and trovafloxacin had a moderate effect, with a 1.5-to 2.5-fold reduction in bacterial numbers (3.4 Ϯ 1.6, 4.0 Ϯ 1.4 and 4.3 Ϯ 1.6 log 10 cfu/lungs, respectively; P Ͻ 0.05). The activity of amoxycillin-clavulanate, ciprofloxacin, cefuroxime and azithromycin was poor, producing bacterial counts that were not significantly different from those in control animals (4.2 Ϯ 2.5, 5.3 Ϯ 0.8, 6.1 Ϯ 1.1 and 5.5 Ϯ 1.2 log 10 cfu/lungs, respectively; P Ͼ 0.05).
H. influenzae infection
Following infection with H. influenzae Chesterfield ( -lactamase-negative, ampicillin-resistant), the bacterial count in untreated controls (5.0 Ϯ 1.06 log 10 cfu/lungs) was similar to that in cefuroxime-and azithromycin-treated animals (P Ͼ 0.05) (Figure 2a) . In contrast, gemifloxacin was highly effective, reducing bacterial numbers to below the level of detection (р1.7 log 10 cfu/lungs; P Ͻ 0.01). A similar response was seen with ciprofloxacin, grepafloxacin, levofloxacin and trovafloxacin (р1.7, 1.8 Ϯ 0.2, р1.7 and 2.5 Ϯ 0.7 log 10 cfu/lungs, respectively).
In animals infected with H. influenzae LA 85021 ( -lactamase-positive), gemifloxacin markedly reduced bacterial numbers compared with no treatment (р1.7 log 10 versus 6.85 Ϯ 0.9 log 10 cfu/lungs; P Ͻ 0.01) (Figure 2b) . A similar response was seen with ciprofloxacin, grepafloxacin, levofloxacin and trovafloxacin (P Ͼ 0.05). In contrast, cefuroxime and azithromycin were significantly less effective than gemifloxacin (5.9 Ϯ 1.1 and 5.3 Ϯ 1.2 log 10 cfu/lungs, respectively; P Ͻ 0.01).
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Treatment failure
Treatment failure, where seen, was not found to be caused by the selection of S. pneumoniae or H. influenzae strains with reduced susceptibility to the test agents.
Discussion
Given the increasing spectrum of resistance in common respiratory pathogens, and the empirical approach to therapy in the community setting, it is vital that any drug used for RTI is potent against a range of pathogens and antimicrobial susceptibility profiles. -Lactams (e.g. amoxycillin with or without clavulanate, or cefuroxime) and macrolides (e.g. azithromycin) are currently considered the treatments of choice for community-acquired RTI. However, treatment failures with azithromycin have been reported in clinical studies of acute exacerbation of chronic bronchitis 28, 29 and acute otitis media. 30 Our results confirm previous reports of poor activity for macrolides against experimental infections caused by H. influenzae 30 and may indicate that the published susceptibility breakpoints are too high, as suggested by other workers. 1 In addition, the increasing prevalence of drug-resistant S. pneumoniae has the potential to reduce antimicrobial effectiveness. Quinolones provide a therapeutic alternative in the treatment of RTI. However, older agents, such as ciprofloxacin, have limited activity against Gram-positive organisms. For example, incomplete bacterial eradication and therapeutic failure have been reported with ciprofloxacin against S. pneumoniae infection. 32, 33 Newer quinolones, such as gemifloxacin, trovafloxacin and grepafloxacin, have enhanced activity against Gram-positive organisms. [6] [7] [8] However, their antimicrobial spectra and pharmacokinetics do vary, and this will affect their ability to achieve bacterial eradication.
In this experimental model of RTI, gemifloxacin was more potent than ciprofloxacin, trovafloxacin, grepafloxacin and levofloxacin against all strains of S. pneumoniae. These included macrolide-resistant, penicillin-resistant and penicillin-susceptible strains. Compared with azithromycin, gemifloxacin was more potent against macrolide-resistant strains of S. pneumoniae. Its efficacy against penicillinsensitive pneumococci was equivalent or superior to that of amoxycillin-clavulanate and cefuroxime. Of all the antimicrobial agents tested, gemifloxacin was the most potent against pneumococcal strains with impaired susceptibility to standard antimicrobial agents.
The patterns of antimicrobial activity observed in this study against strains with reduced antimicrobial susceptibility reflect the findings of other studies regarding cross-resistance in pneumococci between -lactams and macrolides. 34, 35 While azithromycin was moderately potent against the penicillin-susceptible strain (S. pneumoniae 1629), it was ineffective against the penicillin-and macrolide-resistant strains (S. pneumoniae 404053 and 406081).
As the production of -lactamase by H. influenzae is widespread, 36 we investigated the potency of the test panel of antimicrobial agents against both -lactamase-positive and -negative, ampicillin-resistant strains. The potency of gemifloxacin was marked, and was unaffected bylactamase status. A similar response was recorded with ciprofloxacin, grepafloxacin, levofloxacin, trovafloxacin and tosufloxacin, while cefuroxime and azithromycin were significantly less potent than gemifloxacin.
Most respiratory infections in which pneumococci and H. influenzae are of aetiological significance are managed in the outpatient setting. The excellent potency demonstrated by gemifloxacin in this experimental model of RTI confirms its reported efficacy in vitro against these common respiratory pathogens. [8] [9] [10] [11] [12] [13] In previous studies, gemifloxacin has also demonstrated high potency against the atypical RTI pathogens, Mycoplasma pneumoniae, Legionella pneumophila and Chlamydia pneumoniae. 14, 37 The findings of this study indicate a high potential benefit for the use of gemifloxacin in the empirical treatment of RTI.
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